Premium
Translation of the therapeutic approach of scleral collagen crosslinking (SXL) from animal to human
Author(s) -
RATTUNDE U,
KORBER N,
GOHLER C,
KOCH C,
KARL A,
SCHULDT C,
REICHENBACH A,
FRANCKE M,
WIEDEMANN P,
ISELI HP
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2014.s027.x
Subject(s) - sclera , blue light , stiffness , riboflavin , biomedical engineering , irradiation , materials science , chemistry , surgery , medicine , optoelectronics , composite material , physics , biochemistry , nuclear physics
Purpose In our research project “collagen crosslinking of scleral tissue (SXL)”, the application of riboflavin and blue light has been proved as a possible therapeutic method to increase scleral stiffness. Nevertheless, it is necessary to develop a new application system applicable in human. Methods Rheology was used to investigate changes of sclera stiffness after SXL treatment. An adapted and modified blue light irradiations system has been developed to apply various blue light intensities. Results As a proof of principle, we demonstrate a dose dependent increase of scleral stiffness after application of various blue light energy dose rates. Increased biomechanical stiffness could be induced with light dose rates up to 200 mW/cm². However, the light application system used for animal surgery has serious limitations. The animal experiments revealed relevant technical parameters and helps to design a suitable substance and application system for usage in human. Conclusion The results confirm the idea that SXL by riboflavin and blue light irradiation is an applicable method to increase biomechanical stiffness of scleral tissue and therefore, it might be a treatment for pathologic myopia. For the therapeutic application in patients a special substance application and irradiation system has to be refined and developed further.